Spesolimab Clears Lesions in Generalized Pustular Psoriasis
In phase 2 trial, spesolimab cleared more lesions than placebo, but it was associated with infections, systemic drug reactions
Psoriasis
Otezla Now Approved for Plaque Psoriasis Across All Severities
The approval was based on data from the phase 3 ADVANCE trial.
Yusimry, a Humira Biosimilar Product, Gets FDA Approval
The approval was based on a comprehensive data package demonstrating that Yusimry was highly similar to the reference product, Humira.
Clinically Significant Improvements in Genital Psoriasis Observed With Apremilast
Results from the phase 3 study showed that apremilast met the primary and all secondary endpoints in patients with moderate to severe genital psoriasis.
Deucravacitinib Under Review for Moderate to Severe Plaque Psoriasis
The application is supported by data from the pivotal phase 3 POETYK PSO-1 and POETYK PSO-2, which included patients with moderate to severe plaque psoriasis.
Bimekizumab Significantly Improves Joint, Skin Symptoms in Psoriatic Arthritis
The phase 3 BE OPTIMAL study included 852 adults with active psoriatic arthritis who were biologic disease-modifying antirheumatic drug naïve.
Seven Best Diagnostic Criteria ID’d for Childhood Psoriasis
Presence of 2 or more of these criteria has a sensitivity and specificity of more than 70%, the authors say
First Interchangeable Biosimilar to Humira Gets FDA Approval
The interchangeable biosimilar product may be substituted for the reference product by a pharmacist.
Travel Restrictions Hinder Bimekizumab BLA Review
Bimekizumab is an investigational humanized monoclonal IgG1 antibody that selectively inhibits both interleukin (IL)-17A and IL-17F.
Infection Risk Does Not Seem to Differ Among Biologics for Psoriasis
Differential risk for serious infection or respiratory tract infection, including SARS-CoV-2, not seen among biologics used to treat psoriasis
